Repligen Corporation (NASDAQ:RGEN – Get Free Report)’s share price rose 10.3% during mid-day trading on Thursday . The company traded as high as $124.37 and last traded at $124.7720. Approximately 586,495 shares traded hands during trading, a decline of 39% from the average daily volume of 955,606 shares. The stock had previously closed at $113.17.
Analysts Set New Price Targets
RGEN has been the subject of a number of analyst reports. JPMorgan Chase & Co. reduced their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Wells Fargo & Company reduced their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. KeyCorp reissued an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Barclays boosted their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $142.00 target price on shares of Repligen in a research note on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $166.15.
Read Our Latest Stock Report on RGEN
Repligen Trading Up 11.5%
Repligen (NASDAQ:RGEN – Get Free Report) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter in the previous year, the company earned $0.39 earnings per share. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of RGEN. AQR Capital Management LLC acquired a new position in Repligen during the first quarter worth about $262,000. Jones Financial Companies Lllp grew its holdings in Repligen by 3,850.6% during the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after acquiring an additional 6,238 shares during the period. Goldman Sachs Group Inc. grew its holdings in Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock worth $18,067,000 after acquiring an additional 20,375 shares during the period. Bank of Nova Scotia lifted its stake in Repligen by 88.0% during the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after purchasing an additional 14,860 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in Repligen by 29.7% during the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after purchasing an additional 7,148 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
About Repligen
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Featured Stories
- Five stocks we like better than Repligen
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
- IREN Is Flipping the Switch from Bitcoin to AI
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
